Business Context and Reporting Period
Company: IDEAYA Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 13, 2019
Reporting Period: Third quarter ended September 30, 2019
Business Context: The filing serves as a notification of the Company's third-quarter 2019 financial results and the release of a new corporate presentation. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data points. It references a press release (Exhibit 99.1) containing the actual results. Consequently, the following metrics are not available in the source text:
- Revenue: Not provided in filing text.
- Profit/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Margins: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not provide comparative financial data or specific details regarding material changes versus the prior period. It only confirms the announcement of Q3 2019 results.
Guidance, Outlook, and Management Commentary
Management Commentary: The filing indicates that management released a press release regarding Q3 2019 results and a new corporate presentation. The full text of these communications is contained in Exhibits 99.1 and 99.2, which are not included in the provided input.
Guidance and Risks: No specific forward-looking guidance, risk factors, or contingencies are detailed in the cover sheet text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2019 revenue, net loss, and cash position figures.
- Examine Exhibit 99.2 (Corporate Presentation) for updated clinical trial timelines and strategic outlook.
- Verify the Company's status as an Emerging Growth Company and its election regarding extended transition periods for accounting standards.
- Confirm the trading symbol IDYA on the Nasdaq Global Select Market.